BRIEF-Nabriva Therapeutics anticipate topline data from phase 3 trials in second half of 2017
* Nabriva therapeutics confirms no sample size adjustment required for leap 1 phase 3 trial of lefamulin in community acquired bacterial pneumonia [Source]
Publication Date:Origin: reuters.com
Category: governmentFilingsNews
Topics: phase, pneumonia, bacterial, community acquired, lefamulin, trial, adjustment required, sample, confirms, therapeutics, Nabriva, second, trials, topline, anticipate, Therapeutics, BRIEF-Nabriva
Source: http://feeds.reuters.com/~r/reuters/governmentfilingsNews/~3/WHPoFb4WGKI/idUSASB0AY6S